Introduction
============

Thyroid cancer (TC) is the major endocrine malignancy with estimated 298,000 new cases and 40,000 deaths worldwide in 2012 ([@b1-or-39-03-1197]). Thyroid carcinoma is the fastest-growing cancer with the increasing morbidity rate \>5% due to the advanced diagnostic techniques as well as multiple risk factors. Although the 5-year survival rate for patients with thyroid carcinoma is relatively higher than other malignant neoplasms, the mortality rate of TC has remained ever-increasing over the past decade ([@b2-or-39-03-1197],[@b3-or-39-03-1197]). Thyroid cancer is a heterogeneous disease of 3 histological subtypes: papillary TC (PTC), follicular TC (FTC) and anaplastic TC (ATC) ([@b4-or-39-03-1197]). As the most primary malignant thyroid tumor, PTC accounts for up to 80% of total cases. Although PTC is generally effectively treated with thyroidectomy and hormone therapy, large numbers of unresponsive patients suffer from progressive disease and metastases ([@b5-or-39-03-1197]). Thus, it is urgent to explore the molecular mechanisms underlying PTC for developing effective diagnostic and therapeutic targets.

Non-coding RNAs (ncRNAs) are generally defined as a wide class of RNAs without protein-coding function, but with universal expression in organisms. ncRNAs are loosely split into small ncRNAs and long non-coding RNAs (lncRNAs), both of which have regulatory functions in the various biological processes ([@b6-or-39-03-1197]). The well-documented microRNAs (miRNAs; \~22 nucleotides long) belong to small ncRNAs and are regarded as vital regulators of cellular gene expression network ([@b7-or-39-03-1197]). lncRNAs are transcripts \>200 nucleotides with tissue-specific expression, but neither has significant open reading frames nor translate into proteins ([@b8-or-39-03-1197]). Accumulating studies over the past decades have altered the understanding of lncRNA from 'dark matter' to important transcriptional and post-transcriptional regulators. Abnormally expressed lncRNAs participate in tumorigenesis by interrupting biological processes of both oncogenic and tumor suppressive pathways ([@b9-or-39-03-1197]). In 2011, Pandolfi *et al* put forward the competitive endogenous RNA (ceRNA) hypothesis that specific RNAs (including lncRNA, mRNA, pseudogene and circular RNA) can impair miRNA activity by sponging miRNA via common miRNA response elements (MREs) and upregulate target RNA expression subsequently ([@b10-or-39-03-1197]). This hypothesis introduced a new RNA-RNA crosstalk theory that can generally regulate gene expression. In addition, the promising area of disclosing the landscape of the ceRNA mechanism has evoked much interest. Therefore, the lncRNA-miRNA-mRNA networks that may lead to tumor development and progression have already been constructed in many malignancies, including gastric cancer ([@b11-or-39-03-1197]), hepatocellular carcinoma ([@b12-or-39-03-1197]), glioblastoma ([@b13-or-39-03-1197]) and lung adenocarcinoma ([@b14-or-39-03-1197]).

Recent studies have preliminarily revealed several ceRNA regulatory interactions and corresponding mechanisms in thyroid carcinoma. lncRNA H19 was certified to act as ceRNA by sponging miR-17-5p to upregulate the target gene YES1, demonstrating a potential ceRNA crosstalk including H19, miR-17-5p, and YES1 in thyroid cancer pathogenesis ([@b15-or-39-03-1197]). A bioinformatic ceRNA analysis revealed that stem cell factor SOX2 could be functionally co-regulated with other genes by crosstalk mediated by several miRNAs in anaplastic thyroid carcinoma ([@b16-or-39-03-1197]). Furthermore, both a ceRNA network built by microarray analysis of 5-paired clinical samples and a protein-coding modulatory network that regulated immune responses have been reported in PTC ([@b17-or-39-03-1197],[@b18-or-39-03-1197]). However, a whole genome-wide analysis of the lncRNA-miRNA-mRNA regulatory network of papillary thyroid cancer with large-scale sample size is still lacking.

In the present study, we comprehensively investigated both RNA and miRNA sequencing data of 348 PTC primary tumor tissues and 58 non-cancerous thyroid samples from The Cancer Genome Atlas (TCGA) data matrix to obtain the aberrantly expressed lncRNAs, miRNAs, and mRNAs. Next, an lncRNA-associated ceRNA network of papillary thyroid cancer was built based on ceRNA theory. The expression levels of the important lncRNAs involved in ceRNA crosstalk were also assessed for their prognostic values in patients with papillary thyroid cancer.

Materials and methods
=====================

### Date collection

PTC patients (502) were obtained from the TCGA consortium. Inclusion criteria included: i) patients diagnosed with PTC but with no other malignancies; ii) patients with complete clinical data, including age, sex, race, the American Joint Committee on Cancer (AJCC) TNM and pathologic stage; iii) patients with overall survival time \<2,000 days; and iv) patients with complete lncRNA, mRNA and miRNA expression profiles. In total, 348 patients (cohort T) who were pathologically diagnosed as PTC and 58 normal samples (cohort N) were enrolled in downstream analysis. The RNAseq and miRNAseq data (level 3) generated from IlluminaHiseq_RNASeq and IlluminaHiseq_miRNASeq sequencing platform was downloaded from TCGA data portal. The present study followed the publication guidelines of TCGA Research Network (<http://cancergenome.nih.gov/publications/publicationguidelines>). Thus, no further ethical approvals were required.

### Analysis of differentially expressed genes

Differential expression analysis was carried out to identify differentially expressed lncRNAs, mRNAs and miRNAs (DElncRNAs, DEmRNAs, DEmiRNAs) between cohort T and N, by the R/Bioconductor package of edgeR ([@b19-or-39-03-1197]) with the cut-off value of \|log~2~FC\|\>1 and FDR \<0.05 (FC, fold change; FDR, false discovery rate).

### CeRNA network construction

lncRNA-miRNA interactions were predicted by miRcode (<http://www.mircode.org/>) ([@b20-or-39-03-1197]). TargetScan (<http://www.TargetScan.org/mamm_31/>), miRTarBase (<http://mirtarbase.mbc.nctu.edu.tw/>) and miRanda (<http://www.microrna.org/microrna/home.do>) were cooperatively utilized to predict the mRNAs targeted by miRNAs ([@b21-or-39-03-1197],[@b22-or-39-03-1197]). According to the above lncRNA/miRNA and miRNA/mRNA interactions, the Cytoscape (version 3.5.1) was utilized to build and visualize the lncRNA-miRNA-mRNA network ([@b23-or-39-03-1197]).

### Functional annotation

The Database for Annotation Visualization and Integrated Discovery (DAVID) online tool (<https://david.ncifcrf.gov/>) was used to conduct the functional and pathway enrichment analyses. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed to detect the potential biological functions and pathways of the DEmRNAs involved in the network (P-value \<0.05).

### Statistical analysis

Unpaired t-test was applied to identify differentially expressed genes between cohort T and N, and to find out DElncRNAs between different pathological subgroups of cohort T. The univariate Cox proportional hazards regression was used to estimate the expression of DElncRNAs in ceRNA network with overall survival. Kaplan-Meier survival analysis was used to analyze the correlation between lncRNA expression and PTC patient prognosis.

Results
=======

### Patient characteristics

The clinical and pathological information of patients in cohort T was summarized in [Table I](#tI-or-39-03-1197){ref-type="table"}. The median age of all patients in cohort T was \~48 years. The distributions of sex and race showed that white female patients accounted for the majority in the male/female ratio of 2.8/1 and white race ratio of 80.2%. The 3 histopathological variants, classical PTC (CPTC), follicular PTC (FPTC) and tall-cell PTC (TCPTC) represented 75.9, 14.3 and 9.8%, respectively. The proportions and distributions of these patients clinical characteristics were consistent with previous studies ([@b24-or-39-03-1197],[@b25-or-39-03-1197]).

### Differentially expressed lncRNA, mRNA and miRNA

Considering the dissimilarity among the 3 PTC variants, RNA expression levels in the 3 PTC variants (cohort T) vs. normal tissues (cohort N) were investigated, respectively. Genes with an absolute fold change \>2 and FDR value \<0.05 were considered as discriminatively expressed. As a result, a total of 780 lncRNAs and 1,700 mRNAs were detected to be collectively dysregulated in carcinoma tissues of 3 PTC variants compared with normal tissues. Among them, 440 and 340 lncRNAs were commonly elevated and downregulated, meanwhile, 973 and 727 mRNAs were collectively upregulated and downregulated, respectively. Filtering analysis with the same criteria (\|log~2~FC\|\>1 and FDR \<0.05) also identified 43 miRNAs differentially expressed between 3 PTC variants and normal thyroid tissues, among them 27 upregulated and 16 downregulated ([Fig. 1](#f1-or-39-03-1197){ref-type="fig"}) (data not shown). To visualize the most significant lncRNAs, we selected the top 50 upregulated and top 50 downregulated lncRNAs to construct expression heatmaps ([Fig. 2](#f2-or-39-03-1197){ref-type="fig"}) (data not shown). The data suggested that the expression profiles of DElncRNAs can distinguish PTC tissues from normal tissues.

### ceRNA network in PTC

In the next step, we predicted the potential interactions among the above collectively dysregulated genes based on ceRNA hypothesis by computational analysis to further understand the function of DElncRNAs. Thirteen specific DEmiRNAs were identified to interact with 45 DElncRNAs through miRNA response elements by miRcode online tools ([Table II](#tII-or-39-03-1197){ref-type="table"}). To improve the predictive accuracy, TargetScan, miRTarBase and miRanda databases were combined to predict the candidate mRNA targets of the 11 DEmiRNAs. After excluding the mRNAs that were not involved in the 1,700 DEmRNAs, 86 mRNAs were enrolled to create the ceRNA network ([Table III](#tIII-or-39-03-1197){ref-type="table"}). Finally, the ceRNA network that involved 45 lncRNAs, 13 miRNAs and 86 mRNAs was visualized using Cytoscape software based on the interactions among lncRNAs, miRNAs and mRNAs in [Tables II](#tII-or-39-03-1197){ref-type="table"} and [III](#tIII-or-39-03-1197){ref-type="table"} ([Fig. 3](#f3-or-39-03-1197){ref-type="fig"}).

### Functional analysis of DEmRNAs in the ceRNA network

The function analysis revealed that the 86 DEmRNAs in the above ceRNA network were enriched in 60 GO biological process categories and 7 KEGG categories (P\<0.05). The significant GO biological processes of dysregulated genes were 3 cell adhesion terms (GO:0007155, GO:0007160 and GO:007156) ([Fig. 4](#f4-or-39-03-1197){ref-type="fig"}). [Table IV](#tIV-or-39-03-1197){ref-type="table"} contains the significantly enriched pathways of these DEmRNAs by KEGG analysis. There were two cancer-related pathways, including pathways in cancer and miRNAs in cancer. Notably, transcriptional factor E2F1 had an elevated expression in PTC tissues and was involved as the key component in both cancer-related pathways.

### lncRNAs in relation to clinical outcome

To further understand whether dysregulated lncRNAs were correlated with patient outcome, the 45 DElncRNAs involved in the network were analyzed according to clinical characteristics including sex, race, TNM staging system and pathologic stage. The expression levels of 9 lncRNAs were aberrantly expressed in clinical feature comparisons of cohort T (\|log~2~FC\|\>1 and FDR\<0.05) ([Table V](#tV-or-39-03-1197){ref-type="table"}). Among them, we identified 3 lncRNAs (FAM182A, LINC00402 and LINC00473) differentially expressed in race subgroup. Four upregulated lncRNAs (MIR205HG, C12orf7, TCL6 and LINC00460) and 4 downregulated lncRNAs (GDNF-AS1, LINC00402, LINC00473 and LINC00237) were markedly related to tumor progression. LINC00473 may not only inhibit tumor growth (T3+T4 vs. T1+T2), but also decrease in individuals with poor pathologic stage, suggesting its potential negative role in tumor development of PTC. Overexpression lncRNA LINC00460 was identified to be correlated with the poor pathologic stage.

Kaplan-Meier analysis was applied to investigate overall survival for DElncRNAs in cohort T. Among the 45 DElncRNAs in the ceRNA network, 3 lncRNAs (LINC00284, RBMS3-AS1 and ZFX-AS1) were identified to be associated with overall survival by univariate Cox regression analysis (log-rank, P\<0.05). Kaplan-Meier plots indicated that individuals with relatively higher RBMS3-AS1 expression tended to have shorter overall survival time. On the contrary, LINC00284 and ZFX-AS1 could prolong patient survival time ([Fig. 5A](#f5-or-39-03-1197){ref-type="fig"}). Kaplan-Meier survival analysis was also assessed to estimate overall survival for the potentially associated DEmRNAs of these lncRNAs. Notably, high expression of E2F1 was also predicted to be positively associated with patient survival time ([Fig. 5B](#f5-or-39-03-1197){ref-type="fig"}).

Discussion
==========

PTC is the most frequent endocrine neoplasia characterized by a variety of aberrant molecular events driving tumori-genesis ([@b26-or-39-03-1197]). Currently, much effort has been made to elucidate the roles of ncRNAs involved in tumorigenesis, disease progression and metastasis of PTC ([@b17-or-39-03-1197],[@b27-or-39-03-1197],[@b28-or-39-03-1197]). According to the ceRNA hypothesis, increasing evidence has demonstrated that lncRNAs regulated target genes through microRNAs (miRNAs) competition ([@b29-or-39-03-1197]). To comprehensively identify the landscape regarding how lncRNA-associated ceRNA network affects PTC, the present study analyzed the large-scale sequencing data of PTC patient cohort in TCGA database. We identified the aberrantly expressed lncRNAs, mRNAs and miRNAs, and further successfully constructed the dysregulated lncRNA-associated ceRNA network in PTC by biological prediction. We also identified several lncRNAs and their related mRNAs to be potential prognostic indicators for PTC patients.

In previous studies, several groups have identified numerous abnormally expressed lncRNAs in PTC compared with non-tumor tissues. Two small cohort studies based on microarray sequencing of 3 and 5 pairs of PTC samples, respectively, have identified thousands of significantly dysregulated lncRNAs and validated several DElncRNAs by real-time PCR ([@b18-or-39-03-1197],[@b30-or-39-03-1197]). Xie *et al* reported a ceRNA network in PTC containing 29 lncRNAs, 9 miRNAs and 67 mRNAs by microarray analysis of 5-paired clinical samples ([@b31-or-39-03-1197]). However, lncRNA-associated ceRNA network based on whole-genome gene expression profiling with large study population in PTC has not been described.

In the present study, 780 lncRNAs were detected as commonly dysregulated lncRNAs in 3 PTC variants (CPTC, FPTC and TCPTC) compared with normal tissues, including 440 upregulated and 340 downregulated. Among them, 45 aberrantly expressed lncRNAs were identified in the ceRNA network, and 8 out of them were related to tumor progression. The low expression of an intergenic lncRNA LINC00473 in PTC tumor tissues (\~10-folds) may have potential capacity to promote tumor growth and pathologic stage. It has been identified to have prognostic value for lung cancer in a cyclic AMP-dependent manner ([@b32-or-39-03-1197]). However, whether LINC00473 can utilize similar mechanism to lung cancer in PTC needs further research. LINC00460, a human gene transcribed from chromosome 13, is upregulated in various cancers, including thyroid cancer ([@b33-or-39-03-1197]). The upregulation of LINC00460 was also observed in the present study and was positively correlated with the pathologic stage of PTC. It was reported that LINC00460 participated in a series of biological processes (e.g., metabolic process, chromatin modification, cell cycle and cell death) and showed prognostic prediction power for head and neck squamous cell carcinoma ([@b33-or-39-03-1197],[@b34-or-39-03-1197]). These findings implied that LINC00460 may functionally be involved in the tumorigenesis of PTC. Moreover, RBMS3-AS1 and ZFX-AS1 also had potential values for PTC patients prognosis. Since these lncRNAs are reported for the first time as prognostic predictors, much effort deserves to be made to elucidate their biological function in neoplasms. Although the lncRNAs listed in [Table V](#tV-or-39-03-1197){ref-type="table"} had no statistical significance in Kaplan Meier analysis (data not shown), both the lnRNAs that were associated with the progression of PTC and with patients\' overall survival may have potential roles in PTC and are worth studying in the future.

However, having identified several specific lncRNAs for PTC, the present study drew a comprehensive ceRNA network, which revealed the complexity of the regulatory relationships among lncRNAs, miRNAs and mRNAs. E2F1, the best-studied E2F member, was significantly upregulated in PTC tumor tissues, which was consistent with a previous study ([@b35-or-39-03-1197]). E2F1 was involved in both cancer-related pathways: pathways in cancer and miRNAs in cancer. Although previously E2F1 was found to promote thyroid carcinogenesis ([@b35-or-39-03-1197]), our results demonstrated that high expression of E2F1 could prolong survival time of PTC patients, which strongly suggested its tumor-suppressive activity in thyroid cancer. Thus, we supposed that E2F1 may exhibit both oncogenic and tumor suppressive properties in thyroid cancer resulting from its capacity to induce tumor cell proliferation and apoptosis ([@b36-or-39-03-1197]--[@b38-or-39-03-1197]). The ceRNA network predicted that E2F1 was a target gene of miR-205. It was consistent with the previous study that miR-205 induced cancer senescence by regulating E2F1 and ultimately suppressed melanoma development ([@b39-or-39-03-1197]). Our bioinformatic analysis predicted that miR-205 may interact with LINC00284, the increased expression of which was also positively correlated with the prognosis of PTC patients. Although the function of LINC00284 is poorly annotated, it is conceivable that LINC00284 may act as a ceRNA to interact with miR-205 and E2F1 in PTC.

There are several limitations in the present study. First, ceRNA hypothesis indicates that lncRNAs can serve as ceRNAs to regulate expression of the target genes by merging miRNAs. Therefore, the complex ceRNA network of PTC was built based on this hypothesis using biological prediction. Second, the ceRNA network with hundreds of connections suggested that one lncRNA connected with a number of miRNAs and relevant mRNAs. In this regard, our further study may focus on conducting experiments to validate several crucial interactions, particularly to verify the key interactions we discussed above and determine the roles of these lncRNAs as ceRNA in PTC. Third, the 3 lncRNAs that were aberrantly expressed in race need extensive validation studies, which must be based on a large-scale multiracial cohort.

In conclusion, we identified various dysregulated lncRNAs, miRNAs and mRNAs between tumor and non-tumor samples by genome-wide analysis of a large PTC patient cohort from TCGA. The lncRNA-related ceRNA network will be useful to guide further investigation concerning the involved lncRNAs of their definite mechanisms and functions in the tumorigenesis of PTC.
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###### 

Demographic and clinical characteristics of 348 patients with papillary thyroid cancer in cohort T.

  Parameter/feature             Cohort T (n=348) (%)
  ----------------------------- ----------------------
  Age, years (mean ± SD)        48.1±15.9
  Sex                           
    Male                          92 (26.4)
    Female                      256 (73.6)
  Race                          
    Asian                         46 (13.2)
    Black or African American   22 (6.3)
    American Indian or            1 (0.3)
    Alaska native               
    White                       279 (80.2)
  Subtype                       
    CPTC                        264 (75.9)
    FPTC                          50 (14.3)
    TCPTC                       34 (9.8)
  Pathologic stage              
    I                           192 (55.2)
    II                          28 (8.0)
    III                           88 (25.3)
    IV                            40 (11.5)
  Tumor size                    
    T1                          105 (30.2)
    T2                          108 (31.0)
    T3                          116 (33.3)
    T4                          17 (4.9)
    TX                            2 (0.6)
  Lymph node                    
    N0                          164 (47.2)
    N1                          157 (45.2)
    NX                          27 (7.6)
  Metastasis status             
    M0                          231 (66.4)
    M1                            6 (1.7)
    MX                          111 (31.9)

SD, standard deviation; PTC, papillary thyroid cancer; CPTC, classical PTC; FPTC, follicular PTC; TCPTC, tall-cell PTC.

###### 

Putative miRNAs that may target lncRNAs by miRNA response elements.

  lncRNA         miRNAs                                                          lncRNA         miRNAs
  -------------- --------------------------------------------------------------- -------------- ------------------------------------------------------------------------------------------------------------
  AC108463.1     miR-221, miR-222, miR-876, miR-150, miR-205                     LINC00475      miR-506, miR-150, miR-205
  ARHGEF26-AS1   miR-146b, miR-187, miR-508, miR-205                             LINC00487      miR-31, miR-506, miR-205
  C10orf91       miR-146b, miR-876                                               LY86-AS1       miR-375, miR-31, miR-187, miR-506, miR-150, miR-184
  C12orf77       miR-221, miR-222, miR-31, miR-150                               MIR181A2HG     miR-205
  CYP1B1-AS1     miR-150, miR-205                                                MIR205HG       miR-221, miR-222, miR-31, miR-506, miR-150, miR-205
  DLEU2          miR-221, miR-222, miR-144, miR-375, miR-506, miR-150, miR-205   MIR4500HG      miR-144, miR-31, miR-150
  FAM182A        miR-146b, miR-144, miR-876, miR-506, miR-150, miR-205           MIRLET7DHG     miR-375, miR-205
  FAM95B1        miR-221, miR-222, miR-375, miR-31, miR-506, miR-150, miR-184    MLIP-AS1       miR-221, miR-222, miR-144, miR-150
  GDNF-AS1       miR-187                                                         MUC19          miR-146b, miR-221, miR-222, miR-144, miR-375, miR-31, miR-187, miR-508, miR-876, miR-150, miR-205, miR-184
  GLIS3-AS1      miR-876, miR-506                                                P4HA2-AS1      miR-508, miR-876, miR-150, miR-205
  HCG22          miR-31, miR-508, miR-876, miR-506                               PRICKLE2-AS2   miR-144
  LINC00092      miR-150, miR-184                                                RBMS3-AS1      miR-508
  LINC00113      miR-150                                                         RNU12          miR-506
  LINC00237      miR-205                                                         SFTA1P         miR-221, miR-222
  LINC00284      miR-508, miR-506, miR-205                                       SOX21-AS1      miR-146b
  LINC00330      miR-876, miR-150, miR-205                                       SPANXA2-OT1    miR-375
  LINC00365      miR-146b                                                        ST7-AS1        miR-506
  LINC00402      miR-146b, miR-506, miR-150                                      SYNPR-AS1      miR-375
  LINC00423      miR-31, miR-150                                                 TCL6           miR-221, miR-222, miR-144, miR-375, miR-31, miR-187, miR-150, miR-205
  LINC00449      miR-150                                                         TPRG1-AS1      miR-150
  LINC00457      miR-144, miR-150                                                TTLL10-AS1     miR-146b, miR-184
  LINC00460      miR-221, miR-222, miR-150                                       ZFX-AS1        miR-150
  LINC00473      miR-146b, miR-150                                                              

###### 

miRNAs targeting mRNAs in papillary thyroid carcinoma.

  miRNA      mRNAs targeted by miRNA
  ---------- -----------------------------------------------------------------------------------------------------------------------------------------------------
  miR-144    FGA, ARAP2, PLAG1, FGB, MET, TGFB1, LIFR, BCL2L11, ELL2, GRIK3
  miR-146b   MMP16
  miR-150    BCL11B, STAC2, CORO2A, TMEM174, SPIB, F2R, PLXDC1, KCNK5, HIP1, NOTCH3, FHDC1, SRCIN1, TNFSF15, TMEM92, EGR2, NPHS1, MANEAL, QRFPR, ZMAT3, SIGLEC11
  miR-184    LIFR
  miR-187    MRO
  miR-205    NOX5, TNFSF8, KCTD16, CYR61, SLC25A25, PLCXD2, SLC5A12, C11orf74, F2RL2, LRRK2, E2F1, HOXA11, IL24, B4GALT6, PRR15, SHISA6
  miR-221    PCDHA2, SOX11, PCDHA1, FOS, PCDHA3, PCDHA7, FAM84A, RUNX1, PDGFA, KIT, PCDHA5, TIAM1, DIRAS3, BBC3, BCL2L11, VANGL1, HOXC10, CYP1B1
  miR-222    BBC3, DIRAS3, FOS, VANGL1, KIT, PELI2, FAM84A, MMP1, BCL2L11
  miR-31     DMD, RET, ACBD7, SELE, MMP16, RAB27A, TIAM1, MET, SDC4
  miR-375    KCNN4, CTGF, DUSP6, TNS3, IL1RAP, PLAG1, DPYSL3, NCAM1, PRKX, SAMD11, CLDN1, CDKN2B
  miR-506    ADRB3, QRFPR
  miR-876    C8orf4

###### 

KEGG pathways enriched by DEmRNA involved in the ceRNA network.

  Pathway ID   Description                              P-value     Numbers of DEmRNAs
  ------------ ---------------------------------------- ----------- ------------------------------------------------------------------
  hsa05200     Pathways in cancer                       8.99E-05    E2F1, FOS, RET, CDKN2B, PDGFA, MET, KIT, RUNX1, TGFB1, MMP1, F2R
  hsa04060     Cytokine-cytokine receptor interaction   4.12E-04    PDGFA, IL1RAP, MET, TNFSF15, LIFR, KIT, TGFB1, TNFSF8
  hsa04144     Endocytosis                              0.0043302   ADRB3, RET, MET, KIT, ARAP2, TGFB1, F2R
  hsa05206     MicroRNAs in cancer                      0.0070069   NOTCH3, E2F1, CYP1B1, PDGFA, MET, MMP16, BCL2L11
  hsa05166     HTLV--I infection                        0.018641    E2F1, FOS, EGR2, CDKN2B, PDGFA, TGFB1
  hsa05144     Malaria                                  0.0354242   MET, SELE, TGFB1
  hsa04015     Rap1 signaling pathway                   0.0377107   TIAM1, PDGFA, MET, KIT, F2R

KEGG, Kyoto Encyclopedia of Genes and Genomes.

###### 

The correlation between lncRNA in the ceRNA network and patient characteristics.

  Comparisons                       Downregulated                    Upregulated
  --------------------------------- -------------------------------- ------------------------------
  Race                                                               FAM182A, LINC00402 LINC00473
    (Asian vs. White)                                                
  Tumor size                        GDNF-AS1, LINC00402, LINC00473   
    (T3+T4 vs. T1+T2)                                                
  Lymph node                        LINC00237                        MIR205HG, C12orf77, TCL6
    (N1 vs. N0)                                                      
  Pathologic stage                  LINC00473                        LINC00460
    (Stage III+IV vs. stage I+II)                                    
